Paul Matteis

Stifel

Recent Articles

What Do Analysts Think About the Biopharma Set on Transforming Psychiatry 04/09/2026

Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.

Buy Rating Reaffirmed: ALTO-207 TRD Trial on Track 03/25/2026

Stifel reiterated its rating and price target on Alto Neuroscience Inc. (ANRO:NYSE) after an in-line Q4 2025 earnings report.